Leon VanWormer, MBA’s Post

Coming up a special edition of science journal C2W | Mens & Molecule on #bioprocessing (bio)pharma and single-use technologies 💊 And in this dedicated special there is editorial attention for: ✔ A look back at the successful Single-Use Event 2024  ✔ New technologies, equipment and [single-use] products that will support the advances in bioprocessing  ✔ A #PUPSIT and ANNEX 1 update ✔ The latest developments in cell and gene therapy ✔ Great end-to-end solutions for process intensification So do you now represent a company that supplies equipment or products in this #bioprocessing market? And would you like to present this product range in the right umfeld and to the right audience? Then this magazine is the perfect stage to do this 🚀 For the publication possibilities in this magazine, just respond to this post or by email [email protected]

Did you know Japan ranks high globally in market sophistication and innovation, offering growth opportunities for the cell and gene therapy (CGT) sector? For #CGT companies contemplating foreign direct investment in Japan’s burgeoning market, there are several crucial considerations. JLL partnered with the Alliance for Regenerative Medicine to develop a whitepaper on aspects for both companies and investors to consider such as supply chain, labor and real estate. Access the whitepaper: #JLLLifeSciences #CellAndGeneTherapy #ARM

Creating a closed-process, semi-automated workflow for human #MSCexpansion, harvest, and final fill While commercially available #bioreactor platforms allow for large-scale production of #celltherapies, they are often limited in scaling processes, are inherently inefficient, require skilled personnel, and lack flexibility. Later this month, join Entegris Inc.’s Julien Muzard (Field Applications Technologist) and Donnie Beers (LS Applications Leader, Cell and Gene therapy) as they demonstrate the use of off-the-shelf consumables in a closed semi-automated modular workflow as an alternative, more cost-effective approach compared to "all-in-one" systems. Register for this #webinar below:

It's Day 2 of #ASGCT24 Join us at booth 1962 to discuss industry trends and more in cell and gene therapy. Let's connect! #cellandgenetherapy #markettrends

New Book Alert! 📘🔍 Discover the latest insights into Ion Exchange Chromatography with a comprehensive summary in "Ion Exchange Chromatography and Related Techniques." 🌐👏 #IonExchange #Chromatography #NewBook #AnalyticalDevelopment #CGT #CellAndGeneTherapy #HPLC #ScienceBooks

Great start to #ASGCT24 and ready for Day 2! The meeting excitement is palpable. The cell and gene therapy field is slowly coming back from a cold winter. So far, attendees have been most anticipating: 🔬 Scientific updates (particularly in gene / base / prime editing) 🧬 Competitive intelligence on programs, technologies, and the like 🥳 And of course, the socializing - seeing old and new friends that only comes with getting the field together in one place We are here at booth 1962 with our industry trends data as our backdrop (across cell and gene therapy). Come by and lets talk what it all means for your company, your pipeline, your product roadmap. We're here to help! #biotech #strategy #lifescience

New Book Comprehensively Summarizes the State of the Art in Ion Exchange Many analytes differ by their net charge or charge based domains making #HPLC IEX separations quite effective. This is the case for the cell and gene therapy #CGT industry. IEX is becoming increasingly powerful as a tool for titer, encapsidation, encapsulation, and integrity. Each day, analytical development labs are learning more on how to wield this tool. Herein, two Waters Corporation scientists, Mateusz Imiołek and Szabolcs Fekete, contributed to Professor Pavel Nesterenko and Colin Poole et al's newest book on the subject "Ion Exchange Chromatography and Related Techniques". Their chapter is number 13: “Method development for large molecule IEX separations”. The book is impressively comprehensive! There are 29 chapters in total! Congratulations to all the contributors, who range from Professors Michael Bartlett of The University of Georgia to Anurag Rathore of the Indian Institute of Technology, Delhi. Other industry-based investigators contributed too, including scientists from Bristol Myers Squibb’s Devens, MA facility. https://lnkd.in/emvE2w9B

Capsida Biotherapeutics’ CFO Julie Hakim will be presenting at the upcoming 7th Annual Gene Therapy for Rare Disorder conference. She will be leading the GENE THERAPY DECISION MAKERS’ BOOTCAMP on Tuesday, March 26, from 2:40-4 pm ET.   Julie will be diving into the crucial topic of "Improving Biotech Financial Risk Management," shedding light on pivotal aspects that shape the industry’s financial landscape. The session will cover:   🔹 Developing a framework for allocating money 🔹 Spreading risk across an R&D/clinical pipeline 🔹 Weighing up whether to produce in-house or outsource 🔹 Finetuning the timing of key financial decisions   #GeneTherapy #RareDisorders #Biotech #FinancialManagement #Capsida #IndustryInsights #ConferencePresentation

Cell and gene therapy (CGT) manufacturing is complex and far from standardization. Our CEO and Scientific Founder Jean-Simon Diallo and VP of Scientific Operations Jondavid de Jong highlight key CGT manufacturing challenges and the need for tailored solutions to address these issues. Here are the top 3 insights: 💡 There is no “silver bullet” to tackle manufacturing bottlenecks. A winning strategy combines synergistic technologies for additive enhancement. 💡 There is an increasing emphasis on viral vector quality metrics, given the complexity of CGT manufacturing. Ultimately, the “product is the process”. 💡 Cellular defenses pose a significant challenge to the yield and quality of viral vectors, making it imperative to address them during viral vector manufacturing. What challenges are you seeing in CGT biomanufacturing? Drop it in the comments below! #innovation #biotechnology #biomanufacturing

Creating a closed-process, semi-automated workflow for human #MSCexpansion, harvest, and final fill While commercially available #bioreactor platforms allow for large-scale production of #celltherapies, they are often limited in scaling processes, are inherently inefficient, require skilled personnel, and lack flexibility. Next Thursday, join Entegris Inc.’s Julien Muzard (Field Applications Technologist) and Donnie Beers (LS Applications Leader, Cell and Gene therapy) as they demonstrate the use of off-the-shelf consumables in a closed semi-automated modular workflow as an alternative, more cost-effective approach compared to "all-in-one" systems. Attend to learn about: • Limitations in using commercially available #bioreactor platforms in the development and production of cell and #genetherapies • The creation and use of semi-automated modular workflows • When to deploy off-the-shelf consumables Register for this #webinar below: